|
1
|
Stelzle D, Tanaka LF, Lee KK, Ibrahim
Khalil A, Baussano I, Shah ASV, McAllister DA, Gottlieb SL, Klug
SJ, Winkler AS, et al: Estimates of the global burden of cervical
cancer associated with HIV. Lancet Glob Health. 9:e161–e169. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang S, Xu H, Zhang L and Qiao Y:
Cervical cancer: Epidemiology, risk factors and screening. Chin J
Cancer Res. 32:720–728. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arbyn M, Weiderpass E, Bruni L, de Sanjosé
S, Saraiya M, Ferlay J and Bray F: Estimates of incidence and
mortality of cervical cancer in 2018: A worldwide analysis. Lancet
Glob Health. 8:e191–e203. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park SH, Kim M, Lee S, Jung W and Kim B:
Therapeutic potential of natural products in treatment of cervical
cancer: A Review. Nutrients. 13:1542021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vu M, Yu J, Awolude OA and Chuang L:
Cervical cancer worldwide. Curr Probl Cancer. 42:457–465. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang D, Li Q, Li K, Xiao P and Yin R:
Twist-related protein 1-mediated regulation of mesenchymal change
contributes to the migration and invasion of cervical cancer cells.
Oncol Lett. 10:3107–3112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liao Y, Huang J, Liu P, Zhang C, Liu J,
Xia M, Shang C, Ooi S, Chen Y, Qin S, et al: Downregulation of
LNMAS orchestrates partial EMT and immune escape from macrophage
phagocytosis to promote lymph node metastasis of cervical cancer.
Oncogene. 41:1931–1943. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cohen PA, Jhingran A, Oaknin A and Denny
L: Cervical cancer. Lancet. 393:169–182. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Y, Fan H, Dong D, Liu P, He B, Meng L,
Chen J, Chen C, Lang J and Tian J: Computed tomography-based
radiomic model at node level for the prediction of normal-sized
lymph node metastasis in cervical cancer. Transl Oncol.
14:1011132021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen C, Shen N, Chen Y, Jiang P, Sun W,
Wang Q, Wang Z, Jiang Y, Cheng W, Fu S and Wang S: LncCCLM inhibits
lymphatic metastasis of cervical cancer by promoting STAU1-mediated
IGF-1 mRNA degradation. Cancer Lett. 518:169–179. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roszik J, Ring KL, Wani KM, Lazar AJ,
Yemelyanova AV, Soliman PT, Frumovitz M and Jazaeri AA: Gene
expression analysis identifies novel targets for cervical cancer
therapy. Front Immunol. 9:21022018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Balasubramaniam SD, Balakrishnan V, Oon CE
and Kaur G: Key molecular events in cervical cancer development.
Medicina (Kaunas). 55:3842019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ribatti D, Tamma R and Annese T:
Epithelial-Mesenchymal transition in cancer: A historical overview.
Transl Oncol. 13:1007732020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sheng L and Zhuang S: New insights into
the role and mechanism of partial epithelial-mesenchymal transition
in kidney fibrosis. Front Physiol. 11:5693222020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramesh V, Brabletz T and Ceppi P:
Targeting EMT in Cancer with repurposed metabolic inhibitors.
Trends Cancer. 6:942–950. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Navas T, Kinders RJ, Lawrence SM,
Ferry-Galow KV, Borgel S, Hollingshead MG, Srivastava AK, Alcoser
SY, Makhlouf HR, Chuaqui R, et al: Clinical evolution of
Epithelial-Mesenchymal transition in human carcinomas. Cancer Res.
80:304–318. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh M, Yelle N, Venugopal C and Singh
SK: EMT: Mechanisms and therapeutic implications. Pharmacol Ther.
182:80–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xiong H, Nie X, Zou Y, Gong C, Li Y, Wu H,
Qiu H, Yang L, Zhuang L, Zhang P, et al: Twist1 Enhances hypoxia
induced radioresistance in cervical cancer cells by promoting
nuclear EGFR localization. J Cancer. 8:345–353. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yeeravalli R, Kaushik K and Das A:
TWIST1-mediated transcriptional activation of PDGFRbeta in breast
cancer stem cells promotes tumorigenesis and metastasis. Biochim
Biophys Acta Mol Basis Dis. 1867:1661412021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fattahi F, Saeednejad Zanjani L, Vafaei S,
Habibi Shams Z, Kiani J, Naseri M, Gheytanchi E and Madjd Z:
Expressions of TWIST1 and CD105 markers in colorectal cancer
patients and their association with metastatic potential and
prognosis. Diagn Pathol. 16:262021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Valdes-Mora F, Gomez del Pulgar T, Bandrés
E, Cejas P, Ramírez de Molina A, Pérez-Palacios R, Gallego-Ortega
D, García-Cabezas MA, Casado E, Larrauri J, et al: TWIST1
overexpression is associated with nodal invasion and male sex in
primary colorectal cancer. Ann Surg Oncol. 16:78–87. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang XX, Yin GQ, Zhang ZH, Rong ZH, Wang
ZY, Du DD, Wang YD, Gao RX and Xian GZ: TWIST1 transcriptionally
regulates glycolytic genes to promote the Warburg metabolism in
pancreatic cancer. Exp Cell Res. 386:1117132020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qin Q, Xu Y, He T, Qin C and Xu J: Normal
and disease-related biological functions of Twist1 and underlying
molecular mechanisms. Cell Res. 22:90–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng Y, Dai M, Dong Y, Yu H, Liu T, Feng
X, Yu B, Zhang H, Wu J, Kong W, et al: ZEB2/TWIST1/PRMT5/NuRD
multicomplex contributes to the epigenetic regulation of EMT and
metastasis in colorectal carcinoma. Cancers (Basel). 14:34262022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li J, Khan MA, Wei C, Cheng J, Chen H,
Yang L, Ijaz I and Fu J: Thymoquinone Inhibits the Migration and
Invasive Characteristics of Cervical Cancer Cells SiHa and CaSki In
Vitro by Targeting Epithelial to Mesenchymal Transition Associated
Transcription Factors Twist1 and Zeb1. Molecules. 22:21052017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei X, Wei Z, Li Y, Tan Z and Lin C:
AKR1C1 contributes to cervical cancer progression via regulating
TWIST1 expression. Biochem Genet. 59:516–530. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li J: Targeting claudins in cancer:
Diagnosis, prognosis and therapy. Am J Cancer Res. 11:3406–3424.
2021.PubMed/NCBI
|
|
29
|
Tabaries S and Siegel PM: The role of
claudins in cancer metastasis. Oncogene. 36:1176–1190. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kwon MJ: Emerging roles of claudins in
human cancer. Int J Mol Sci. 14:18148–18180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoon CH, Kim MJ, Park MJ, Park IC, Hwang
SG, An S, Choi YH, Yoon G and Lee SJ: Claudin-1 acts through
c-Abl-protein kinase Cdelta (PKCdelta) signaling and has a causal
role in the acquisition of invasive capacity in human liver cells.
J Biol Chem. 285:226–233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu W and Li M: The role of claudin-4 in
the development of gastric cancer. Scand J Gastroenterol.
55:1072–1078. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hicks DA, Galimanis CE, Webb PG, Spillman
MA, Behbakht K, Neville MC and Baumgartner HK: Claudin-4 activity
in ovarian tumor cell apoptosis resistance and migration. BMC
Cancer. 16:7882016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Neesse A, Griesmann H, Gress TM and Michl
P: Claudin-4 as therapeutic target in cancer. Arch Biochem Biophys.
524:64–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luo Y, Kishi S, Sasaki T, Ohmori H,
Fujiwara-Tani R, Mori S, Goto K, Nishiguchi Y, Mori T, Kawahara I,
et al: Targeting claudin-4 enhances chemosensitivity in breast
cancer. Cancer Sci. 111:1840–1850. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chenhong Di and Jin F: Value of combined
detection of claudin 4 and high-risk human papilloma virus in
high-grade squamous intraepithelial lesion and cervix squamous cell
carcinoma. Zhejiang Da Xue Xue Bao Yi Xue Ban. 47:344–350. 2018.(In
Chinese). PubMed/NCBI
|
|
37
|
Lanczky A and Gyorffy B: Web-Based
survival analysis tool tailored for medical research (KMplot):
Development and implementation. J Med Internet Res. 23:e276332021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Castro-Mondragon JA, Riudavets-Puig R,
Rauluseviciute I, Lemma RB, Turchi L, Blanc-Mathieu R, Lucas J,
Boddie P, Khan A, Manosalva Pérez N, et al: JASPAR 2022: The 9th
release of the open-access database of transcription factor binding
profiles. Nucleic Acids Res. 50:D165–D173. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shu J, Wang X, Yang X and Zhao G: ATM
inhibitor KU60019 synergistically sensitizes lung cancer cells to
topoisomerase II poisons by multiple mechanisms. Sci Rep.
13:8822023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Meng J, Chen S, Han JX, Qian B, Wang XR,
Zhong WL, Qin Y, Zhang H, Gao WF, Lei YY, et al: Twist1 Regulates
Vimentin through Cul2 Circular RNA to Promote EMT in Hepatocellular
Carcinoma. Cancer Res. 78:4150–4162. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shao T, Song P, Hua H, Zhang H, Sun X,
Kong Q, Wang J, Luo T and Jiang Y: Gamma synuclein is a novel
Twist1 target that promotes TGF-β-induced cancer cell migration and
invasion. Cell Death Dis. 9:6252018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang Y, Alexander PB and Wang XF: TGF-β
family signaling in the control of cell proliferation and survival.
Cold Spring Harb Perspect Biol. 9:a0221452017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wrighton KH, Lin X and Feng XH:
Phospho-control of TGF-beta superfamily signaling. Cell Res.
19:8–20. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cho ES, Kang HE, Kim NH and Yook JI:
Therapeutic implications of cancer epithelial-mesenchymal
transition (EMT). Arch Pharm Res. 42:14–24. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hewitt KJ, Agarwal R and Morin PJ: The
claudin gene family: Expression in normal and neoplastic tissues.
BMC Cancer. 6:1862006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chang TL, Ito K, Ko TK, Liu Q,
Salto-Tellez M, Yeoh KG, Fukamachi H and Ito Y: Claudin-1 has tumor
suppressive activity and is a direct target of RUNX3 in gastric
epithelial cells. Gastroenterology. 138:255–265.e1-e3. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chao YC, Pan SH, Yang SC, Yu SL, Che TF,
Lin CW, Tsai MS, Chang GC, Wu CH, Wu YY, et al: Claudin-1 is a
metastasis suppressor and correlates with clinical outcome in lung
adenocarcinoma. Am J Respir Crit Care Med. 179:123–133. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Osanai M, Murata M, Chiba H, Kojima T and
Sawada N: Epigenetic silencing of claudin-6 promotes
anchorage-independent growth of breast carcinoma cells. Cancer Sci.
98:1557–1562. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sauer T, Pedersen MK, Ebeltoft K and Naess
O: Reduced expression of Claudin-7 in fine needle aspirates from
breast carcinomas correlate with grading and metastatic disease.
Cytopathology. 16:193–198. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Leotlela PD, Wade MS, Duray PH, Rhode MJ,
Brown HF, Rosenthal DT, Dissanayake SK, Earley R, Indig FE,
Nickoloff BJ, et al: Claudin-1 overexpression in melanoma is
regulated by PKC and contributes to melanoma cell motility.
Oncogene. 26:3846–3856. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Agarwal R, D'Souza T and Morin PJ:
Claudin-3 and claudin-4 expression in ovarian epithelial cells
enhances invasion and is associated with increased matrix
metalloproteinase-2 activity. Cancer Res. 65:7378–7385. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Uthayanan L and El-Bahrawy M: Potential
roles of claudin-3 and claudin-4 in ovarian cancer management. J
Egypt Natl Canc Inst. 34:242022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zavala-Zendejas VE, Torres-Martinez AC,
Salas-Morales B, Fortoul TI, Montano LF and Rendon-Huerta EP:
Claudin-6, 7, or 9 overexpression in the human gastric
adenocarcinoma cell line AGS increases its invasiveness, migration,
and proliferation rate. Cancer Invest. 29:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lioni M, Brafford P, Andl C, Rustgi A,
El-Deiry W, Herlyn M and Smalley KS: Dysregulation of claudin-7
leads to loss of E-cadherin expression and the increased invasion
of esophageal squamous cell carcinoma cells. Am J Pathol.
170:709–721. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kohmoto T, Masuda K, Shoda K, Takahashi R,
Ujiro S, Tange S, Ichikawa D, Otsuji E and Imoto I: Claudin-6 is a
single prognostic marker and functions as a tumor-promoting gene in
a subgroup of intestinal type gastric cancer. Gastric Cancer.
23:403–417. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Michl P, Barth C, Buchholz M, Lerch MM,
Rolke M, Holzmann KH, Menke A, Fensterer H, Giehl K, Löhr M, et al:
Claudin-4 expression decreases invasiveness and metastatic
potential of pancreatic cancer. Cancer Res. 63:6265–6271.
2003.PubMed/NCBI
|
|
59
|
Hwang TL, Lee LY, Wang CC, Liang Y, Huang
SF and Wu CM: Claudin-4 expression is associated with tumor
invasion, MMP-2 and MMP-9 expression in gastric cancer. Exp Ther
Med. 1:789–797. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ikenouchi J, Matsuda M, Furuse M and
Tsukita S: Regulation of tight junctions during the
epithelium-mesenchyme transition: Direct repression of the gene
expression of claudins/occludin by Snail. J Cell Sci.
116:1959–1967. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kominsky SL, Argani P, Korz D, Evron E,
Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP and Sukumar S:
Loss of the tight junction protein claudin-7 correlates with
histological grade in both ductal carcinoma in situ and invasive
ductal carcinoma of the breast. Oncogene. 22:2021–2033. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Litkouhi B, Kwong J, Lo CM, Smedley JG
III, McClane BA, Aponte M, Gao Z, Sarno JL, Hinners J, Welch WR, et
al: Claudin-4 overexpression in epithelial ovarian cancer is
associated with hypomethylation and is a potential target for
modulation of tight junction barrier function using a C-terminal
fragment of Clostridium perfringens enterotoxin. Neoplasia.
9:304–314. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kwon MJ, Kim SH, Jeong HM, Jung HS, Kim
SS, Lee JE, Gye MC, Erkin OC, Koh SS, Choi YL, et al: Claudin-4
overexpression is associated with epigenetic derepression in
gastric carcinoma. Lab Invest. 91:1652–1667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Qin W, Ren Q, Liu T, Huang Y and Wang J:
MicroRNA-155 is a novel suppressor of ovarian cancer-initiating
cells that targets CLDN1. FEBS Lett. 587:1434–1439. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sonoki H, Sato T, Endo S, Matsunaga T,
Yamaguchi M, Yamazaki Y, Sugatani J and Ikari A: Quercetin
Decreases Claudin-2 Expression Mediated by Up-Regulation of
microRNA miR-16 in Lung Adenocarcinoma A549 Cells. Nutrients.
7:4578–4592. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Suzuki M, Kato-Nakano M, Kawamoto S,
Furuya A, Abe Y, Misaka H, Kimoto N, Nakamura K, Ohta S and Ando H:
Therapeutic antitumor efficacy of monoclonal antibody against
Claudin-4 for pancreatic and ovarian cancers. Cancer Sci.
100:1623–1630. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Fujiwara-Tani R, Mori S, Ogata R, Sasaki
R, Ikemoto A, Kishi S, Kondoh M and Kuniyasu H: Claudin-4: A new
molecular target for epithelial cancer therapy. Int J Mol Sci.
24:54942023. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kato-Nakano M, Suzuki M, Kawamoto S,
Furuya A, Ohta S, Nakamura K and Ando H: Characterization and
evaluation of the antitumour activity of a dual-targeting
monoclonal antibody against claudin-3 and claudin-4. Anticancer
Res. 30:4555–4562. 2010.PubMed/NCBI
|
